

- 12. Eickhoff TC. Nosocomial infections a 1980 view: progress, priorities and prognosis. Am J Med 1981 Feb; 70: 381-8
- Urinary catheter-related infection: routine treatment of asymptomatic bacteriuria not justified. Drug Ther Perspect 1994 Oct 17; 4(8): 7-9
- Clinical and economic considerations in antimicrobial surgical prophylaxis. Drug Ther Perspect 1993 Oct 25; 2(8): 12-4
- Selective decontamination of the digestive tract in patients admitted to ICUs: individual treatment decisions required. Drug Ther Perspect 1994 Oct 3; 4(7): 14-6
- Nightingale CH. Impact of nosocomial infections on hospital costs. Hosp Formul 1993 Jan; 28 Suppl. 1: 51-4
- Humphreys H, Emmerson AM. Control of hospital-acquired infection: accurate data and more resources, not league tables. J Hosp Infect 1993 Oct; 25: 75-8
- 18. Scheckler WE. Surgeon-specific wound infection rates: a potentially

- dangerous and misleading strategy. Infect Control Hosp Epidemiol 1988 Apr; 9(4): 145-6
- Gross PA. Striving for benchmark infection rates: progress in control for patient mix. Proceedings of the Third Decennial International Conference on Nosocomial Infections. Am J Med 1991 Sep 16; 91 Suppl. 3B: 16S-20S
- Kroin J, Cost implications of malpractice and adverse events. Hospital Formulary 1993 Jan; 28 Suppl. 1: 59-61
- Haley RW. Measuring the costs of nosocomial infections: methods for estimating economic burden on the hospital. Proceedings of the Third Decennial International Conference on Nosocomial Infections. Am J Med 1991 Sep 16; 91 Suppl. 3B: 32S-8S
- 22. Mehtar S. How to cost and fund an infection control programme. J Hosp Infect 1993 Sep; 25: 57-69

## **Erratum**

In the article 'Amorolfine: topical therapy for mild onychomycosis' [Drug Ther Perspect 1995 Mar 20; 5 (5): 4-7], the statements 'In vivo activity limited to dermatophytes' and 'Interacts with other drugs' are listed as limitations of terbinafine in table 1; these statements should be deleted.




(ISSN 1172-0360) is published every 2 weeks (24 issues per year) by Adis International Ltd, an independent company, not affiliated with any pharmaceutical manufacturer or association. Delivered internationally by airmail. Subscriptions are for 12 months and start with the next available issue. Back issues are available for purchase through your local Adis International Office.

Annual Subscription Rates:	North America	UK	Europe	Japan	Australia	Rest of World
Personal subscription*	\$US 95	£ 60	SFr 135	¥13 300	\$A 140	\$US 95
Institutional subscription	\$US 195	£125	SFr 270	¥27 300	\$A 280	\$US 195
Student subscription**	\$US 60	£ 40	SFr 85	¥ 8 400	\$A 85	\$US 60

- \* The personal rate is for individuals only and must be prepaid by personal cheque or personal credit card.
- \*\* Please enclose a photocopy of your student ID card with order.

Please allow 4 weeks for receipt of first issue. Extra copy subscription rates available on request.

Subscription enquiries: Contact the Adis International office in your region:



**Europe**: Adis International Ltd, Chowley Oak Lane, Tattenhall, Chester CH3 9GA, England; Tel: (+44) 1829 71155 or toll free 0800 526-498 (UK only), Fax (+44) 1829 70330

Japan: Exclusive subscription agent: Technomics Inc., Nihonbashi TM Building, 1-8-11 Nihonbashi Horidome-cho, Chuo-ku, Tokyo 103, CPO Box 882, Tokyo 100-91, Japan; Tel: (+81) 3 3666 2952, Fax (+81) 3 3666 2730

**Australia**: Adis International Pty Ltd, 9 Rodborough Road, Frenchs Forest, NSW 2086, Australia; Tel: (+61) 2 975-9100, Fax (+61) 2 975-9199

**New Zealand**: Adis International Ltd, P. B. 65901, Mairangi Bay, Auckland 10, New Zealand; Tel: (+64) 9 479-8100, Fax (+64) 9 479-1418

**Rest of World:** Adis International Publications Ltd, 18/F Tung Sun Commercial Centre, 194-200 Lockhart Road, Wanchai, Hong Hong; Tel (+852) 2511-0633, Fax: (+852) 2507-5554

© Copyright 1995 Adis International Ltd. All rights reserved throughout the world and in all languages. No part of this publication may be reproduced, transmitted or stored in any form or by any means either mechanical or electronic including photocopying, recording or through an information storage and retrieval system, without the written permission of the copyright holder.

The appearance of the code at the bottom of each page of an article in this publication indicates the copyright owner's consent that copies of the page may be made for the personal or internal use of specific clients. This consent is given on the condition, however, that the copier pay the stated per copy fee through the Copyright Clearance Center Inc., 222 Rosewood Drive, Danvers, Massachusetts 01923, USA, for copying beyond that permitted by section 107 or 108 of the US Copyright Law. This consent does not extend to other kinds of copying such as copying for general distribution, for advertising or promotional purposes, for creating new collective works, or for resale.

Although great care has been taken in compiling the content of this publication, the publisher and its servants are not responsible or in any way liable for the currency of the information, for any errors, omissions or inaccuracies, or for any consequences arising therefrom. Inclusion or exclusion of any product does not imply its use is either advocated or rejected. Opinions expressed do not necessarily reflect the views of the Publisher, Editor or Editorial Board.

Drugs & Therapy Perspectives is published by Adis International Ltd, 41 Centorian Drive, P.B. 65901, Mairangi Bay, Auckland 10, New Zealand Printed in Hong Kong

